What type of study is this?

This is a Experimental Study study.

September 17, 2025Therapeutic Advances in Medical OncologyOpen Access

State of the art in treatment of small cell lung cancer

View Full Paper

Ask AI

Bookmark

Authors

RBRoya BehrouziIran University of Medical Sciences FBFiona BlackhallUniversity of Manchester

Discussion

Member takes

Implication

Analysis reveals chemotherapy and immune checkpoint inhibitors improve survival in small cell lung cancer patients, indicating new treatment strategies may emerge.

Key Points

Treatment resistance in small cell lung cancer leads to poor overall survival, necessitating new therapies.
Addition of immune checkpoint inhibitors to chemotherapy has shown modest survival improvements in extensive-stage SCLC.
The FDA-approved durvalumab reduces relapse risk after radical chemo-radiotherapy in limited-stage SCLC patients.
Promising novel therapies, including antibody-drug conjugates and bispecific T-cell engagers, are currently in clinical trials.

Cite This Study

Behrouzi et al. (2025) studied this question.

synapsesocial.com/papers/68d45e6231b076d99fa5ecb8 https://doi.org/10.1177/17588359251363518

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals chemotherapy and immune checkpoint inhibitors improve survival in small cell lung cancer patients, indicating new treatment strategies may emerge.

State of the art in treatment of small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

State of the art in treatment of small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider